Thought Leader Video Series: #11 How Do Pharmacies Utilize the Office of the Inspector General (OIG)?

Anthony Calamunci and Brian Dickerson were interviewed by RXinsider on the status of the Pharmacy industry.  Each week FisherBroyles will provide access to the industry specific Q&A interview sessions hosted by RXinsider so you can learn what the newest legal and industry issues are and how to address these issues when running your pharmacy. Please [...]

Client Alert: DIR Report Demonstrates Downside of Drug Rebates for Consumers and Medicare Program

January 26, 2017 — Earlier this month, the U.S. Centers for Medicare & Medicaid Services (CMS) issued an analysis of direct and indirect remuneration (DIR) fees. The data presented in the report makes clear that despite the claims of pharmacy benefit managers (PBMs) to the contrary, DIR fees do not reduce the costs of drugs for [...]

Client Alert: OIG Kicks off the New Year with Another Round of HHS Rule Changes

OIG Kicks off the New Year with Another Round of HHS Rule Changes Office of Inspector General Implements Important Changes to Exclusion Rules Continuing an onslaught of end-of-administration rule changes, the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services (HHS) today published a 100-plus page final rule implementing a [...]

OIG Issues Final Rule Enlarging Civil Penalties and Amending Safe Harbors Under Anti-Kickback Statute

On December 7, 2016, the HHS Office of Inspector General published the long‐awaited final rule (the Rule) amending the safe harbors under the Anti‐Kickback Statute and the civil monetary penalty (CMP) rules under the Affordable Care Act (ACA). The rule changes become effective on January 6, 2017. The new and revised safe harbors protect certain payment practices [...]